본문 바로가기
KERD
논문KCI 등재

固眞飮子가 Alzheimer Disease 병태모델의 신경세포 손상에 미치는 영향

Effect of Gojineumja(Guzhenyinzi) on Neural Tissue Degeneration in Mouse Model of Alzheimer Disease

정인철|이상룡|김현주
대한한방신경정신과학회 (The Korean Society Of Oriental Neuropsychiatry)|2009.06|동의신경정신과학회지 (The Korean Society of Oriental Neuropsychiatry)|제20권 제2호|pp. 31-46

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

GFAPAlzheimer's disease(AD)Gojineumja(GJEJ)Caspase 3
주제분류한의학

초록

Objectives : This experiment was designed to investigate the effect of Gojineumja(Guzhenyinzi, GJEJ) on damaged neural tissue in cultured glial cells and in the mouse brain tissue. Methods : The effects of the GJEJ on activation of astrocytes and caspase 3-positive cell counts in cultured glial cells administered with β-amyloid peptide were investigated. The effects of the GJEJ on levels of glial fibrillary acidic protein(GFAP)-positive reactive astrocyets and caspase 3-positive cells in the hippocampal subfields in the rats administered with scopolamine were investigated. Results : 1. GJEJ reduced levels of activated astrocytes and caspase 3-positive cell counts in cultured glial cells administered with β-amyloid peptide. 2. GJEJ reduced levels of GFAP-positive reactive astrocyets and caspase 3-positive cells in the hippocampal subfields in the rats administered with scopolamine. Conclusions : The present data suggest that GJEJ may have a protective function of neuronal and non-neuronal cells in damaged neural tissue caused by AD-like stimulations. Further studies on identification of effective molecular components of GJEJ and their interactions with damaged neural cells would be important for understanding molecular mechanism and may be further applicable for the development of therapeutic strategies.

Abstract

Objectives : This experiment was designed to investigate the effect of Gojineumja(Guzhenyinzi, GJEJ) on damaged neural tissue in cultured glial cells and in the mouse brain tissue. Methods : The effects of the GJEJ on activation of astrocytes and caspase 3-positive cell counts in cultured glial cells administered with β-amyloid peptide were investigated. The effects of the GJEJ on levels of glial fibrillary acidic protein(GFAP)-positive reactive astrocyets and caspase 3-positive cells in the hippocampal subfields in the rats administered with scopolamine were investigated. Results : 1. GJEJ reduced levels of activated astrocytes and caspase 3-positive cell counts in cultured glial cells administered with β-amyloid peptide. 2. GJEJ reduced levels of GFAP-positive reactive astrocyets and caspase 3-positive cells in the hippocampal subfields in the rats administered with scopolamine. Conclusions : The present data suggest that GJEJ may have a protective function of neuronal and non-neuronal cells in damaged neural tissue caused by AD-like stimulations. Further studies on identification of effective molecular components of GJEJ and their interactions with damaged neural cells would be important for understanding molecular mechanism and may be further applicable for the development of therapeutic strategies.

참고문헌 (58)

  1. Blennow K, "Alzheimer's disease", Lancet, 368(9533), pp.387~403 (2006)
  2. 이광우, "임상신경학", pp.203~208 (2002), 고려의학
  3. Selkoe DJ, "Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease", J Clin Invest, 110(10), pp.1375~1381 (2002)
  4. Dodart JC, "Overview on rodent models of Alzheimer's disease", Curr Protoc Neurosci, 9(9), pp.22~ (2005)
  5. Götz J, "Animal models of Alzheimer's disease and frontotemporal dementia", Nat Rev Neurosci, 9(7), pp.532~544 (2008)
  6. Selkoe DJ, "Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics", Annu Rev Pharmacol Toxicol, 43, pp.545~584 (2003)
  7. Winters Boyer D, "Paradoxical Facilitation of Object Recognition Memory after Infusion of Scopolamine into Perirhinal Cortex: Implications for Cholinergic System Function", J. Neurosci, 26, pp.9520~9529 (2006)
  8. During MJ, "An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy", Science, 287(5457), pp.1453~1460 (2000)
  9. Elliott J Mufson, "Cholinergic system during the progression of Alzheimer’s disease; therapeutic implications", Expert Review of Neurotherapeutics, 8(11), pp.1703~1718 (2008)
  10. 張介賓, "張氏景岳全書", pp.610~611 (1978), 翰成社
  11. 錢鏡湖, "辨證奇問全書", pp.222~225 (1990), 甘地出版社
  12. 陳士鐸, "石室秘錄", pp.125~ (1991), 中國中醫藥出版社
  13. 洪元植, "精校黃帝內經素問", pp.37~ (1985), 東洋醫學硏究院
  14. 朱震亨, "金櫃鉤玄", pp.306~307 (1992), 鼎談出版社
  15. 대한한방신경정신과학회, "한방신경정신의학", pp.311~320 (2007), 집문당
  16. 李梴, "編註醫學入門", pp.419~420 (1988), 南山堂
  17. 許浚, "東醫寶鑑, 重版", pp.447~ (1966), 南山堂
  18. 김현수, "洗心湯 열수추출물, 초미세분말제형이 Alzheimer's Disease 병태 모델에 미치는 영향", 동의생리병리학회지, 21(3), pp.688~699 (2007), 대한동의병리학회
  19. 최강욱, "聰明湯과 木槿皮聰明湯 열수추출물, 초미세분말제형이 microglia 및 기억력 감퇴 병태모델에 미치는 영향", 동의생리병리학회지, 20(5), pp.1200~1210 (2006), 대한동의병리학회
  20. 강대원, "固眞飮子가 methotrexate로 유발된 흰쥐의 免役機能低下에 미치는 影響(영향)", 대한한방내과학회지, 25(4), pp.117~128 (2004), 대한한방내과학회
  21. Banker G, "Culturing nerve cells,second edition" (2002), MIT Press
  22. National Institute on Health, Progress Report on Alzheimer's Disease, "National Institute on Aging", ~ (1999)
  23. Cacquevel M, "Cytokines in neuroinflammation and Alzheimer's disease", Current Drug Targets, 5(6), pp.529~534 (2004)
  24. Kuhl DE, "In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease", Neurology, 52(4), pp.691~699 (1999)
  25. Mhatre M, "Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets", Journal of Alzheimers disease, 6(2), pp.147~157 (2004)
  26. 안준익, "Beta-amyloid의 분자생물학", 한양의대학술지, 21(1), pp.11~16 (2001)
  27. Kuhl DE, "In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease", Neurology, 52(4), pp.691~699 (1999)
  28. de Vente J, "NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain ; effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis", Eur J Neurosci, 12(2), pp.507~519 (2000)
  29. Trabace L, "Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease", J Pharmacol Exp Ther, 294(1), pp.187~194 (2000)
  30. 李尙仁, "改訂 增補版", pp.51~60 (1981), 修書院
  31. 辛民敎, "原色 臨床本草學, 改訂4版", pp.166~167 (1994), 永 林社
  32. 上海中醫學院, "中草藥學", pp.200~202 (1983), 商務印書館
  33. Eckert A, "Increased apoptotic cell death in sporadic and genetic Alzheimer's disease", Ann N Y Acad Sci, 1010, pp.604~609 (2003)
  34. Standridge JB, "Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease", Curr Alzheimer Res, 3(2), pp.95~108 (2006)
  35. Unger JW, "Glial reaction in aging and Alzheimer's disease", Microsc Res Tech, 43(1), pp.24~28 (1998)
  36. Okada S, "Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury", Nat Med, 12(7), pp.829~834 (2006)
  37. Rich T, "Apoptosis: the germs of death", Nat Cell Biol, 1(3), pp.E69~E71 (1999)
  38. Vassar R, "Caspase-3 cleavage of GGA3 stabilizes BACE: implications for Alzheimer's disease", Neuron, 54(5), pp.671~673 (2007)
  39. Yee AS, "Convulsant and anticonvulsant effects on spontaneous CA3 population bursts", J Neurophysiol, 89(1), pp.427~441 (2003)
  40. Wallenstein GV, "Functional transitions between epileptiform-like activity and associative memory in hippocampal region CA3", Brain Res Bull, 43(5), pp.485~493 (1997)
  41. Weiss C, "The M1 Muscarinic Agonist CI-1017 Facilitates Trace Eyeblink Conditioning in Aging Rabbits and Increases the Excitability of CA1 Pyramidal Neurons", J. Neurosci, 20, pp.783~790 (2000)
  42. Nobili L, "Cholinergic modulation, visual function and Alzheimer's dementia", Vision Res, 37(24), pp.3559~3571 (1997)
  43. Saber AJ, "Combined β-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with β-adrenergic antagonists", Neuropsychopharmacology, 28(7), pp.1247~1256 (2003)
  44. Hartmann J, "Central cholinergic functions in human amyloid precursor protein knock-in", presenilin-1 transgenic mice, 2004, pp.125(4), 1009~1017
  45. Bellucci A, "Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice", Neurobiol Dis, 23(2), pp.260~272 (2006)
  46. Liskowsky W, "Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein", Int J Dev Neurosci, 24(2), pp.149~156 (2006)
  47. Litvan I, "What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia", Neurology, 45(2), pp.387~389 (1995)
  48. Kobayashi K, "Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease", J Alzheimers Dis, 6(6), pp.623~632 (2004)
  49. Marco L, "Galanthamine, a natural product for the treatment of Alzheimer's disease", Recent Patents CNS Drug Discov, 1(1), pp.105~111 (2006)
  50. Kertesz A, "Galantamine in frontotemporal dementia and primary progressive aphasia", Dement Geriatr Cogn Disord, 25(2), pp.178~185 (2008)
  51. Villarroya M, "An update on the pharmacology of galantamine", Expert Opin Investig Drugs, 16(12), pp.1987~1998 (2007)
  52. Razay G, "Galantamine in Alzheimer's disease", Expert Rev Neurother, 8(1), pp.9~17 (2008)
  53. Raschetti R, "Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials", PLoS Med, 4(11), pp.338~ (2007)
  54. Hansen RA, "Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis", Clin Interv Aging, 3(2), pp.211~225 (2008)
  55. Winblad B, "Safety and efficacy of galantamine in subjects with mild cognitive impairment", Neurology, 70(22), pp.2024~2035 (2008), GAL-INT-11[DOI]
  56. Leung LW, "Intrinsic membrane potential oscillations in hippocampal neurons in vitro", Brain Res, 553(2), pp.261~274 (1991)
  57. Leung LS, "Cholinergic Activity Enhances Hippocampal Long-Term Potentiation in CA1 during Walking in Rats", J. Neurosci, 23, pp.9297~9304 (2003)
  58. Houser CR, "Interneurons of the dentate gyrus: an overview of cell types, terminal fields and neurochemical identity", Prog Brain Res, 163, pp.217~232 (2007)

관련 논문AI추천

Alzheimer's Disease 병태모델에서 鹿茸大補湯의 신경세포 보호효과이상룡, 정명희, 정인철대한한방신경정신과학회 · 동의신경정신과학회지2009 · 제20권 제2호蔘笭白朮散이 Alzheimer's Disease 동물모델의 Astrocyte 활성화 및 Apoptosis에 미치는 영향이상룡한의병리학회 · 동의생리병리학회지2009 · 제23권 제2호獨活地黃湯이 βA로 유도된 Alzheimer's Disease 병태 모델에 미치는 영향이상룡, 전미연대한한방신경정신과학회 · 동의신경정신과학회지2010 · 제21권 제1호총명탕, 원지, 석창포가 베타아밀로이드로 유발된 학습과 기억장애에 미치는 영향박은경, 손낙원, 손영주, 심은섭, 정혁상대한한방내과학회 · 대한한방내과학회지2008 · 제29권 제3호人蔘養榮湯이 Aβ를 처리한 PC12 세포와 생쥐의 손상 뇌신경조직에 미치는 영향이상룡, 장영주, 정인철대한한방신경정신과학회 · 동의신경정신과학회지2010 · 제21권 제1호癡呆病態모델에서 天麻의 神經細胞 損傷 保護效果강재현, 구병수, 권영미, 김근우, 박세환, 정영수대한한방신경정신과학회 · 동의신경정신과학회지2010 · 제21권 제2호

이 간행물의 다른 논문 (19건)

Alzheimer's Disease 병태모델에서 鹿茸大補湯의 신경세포 보호효과정인철, 정명희, 이상룡pp. 1-17H2O2로 유도된 산화적 스트레스에 대한 壯元丸加減方의 PC 12 cell 에서의 항산화 효과류영수, 김태헌, 임정현, 이상원, 박용훈, 강형원, 손일홍pp. 19-29三精丸이 高脂肪 食餌 흰 쥐의 비만에 미치는 영향김근우, 구병수, 김지형pp. 47-60여성에 있어서 화병과 기타 질환과의 관련성 연구정하룡, 고상백, 신미란, 공경환, 이재혁, 유준상, 고호연, 박종구pp. 61-70익명의 알코올 중독자 모임의 불안, 우울에 대한 효과 연구김태헌, 손현수, 김지훤, 김회영, 강지홍, 심소라, 박보라pp. 71-84
원문 보기